Braveheart Bio, Inc. Common Stock BRVE
$25.02
-14.32%
at last close
Analyst Consensus
- Consensus Rating
- Buy (5 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $45.25
- Implied Upside
- +80.9%
- Price Target Range
- $40.00 – $48.00
- Analysts (12 mo)
- 5
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-31 | Goldman SachsSalveen Richter |
Initiates coverage on | Buy | $48 |
| 2026-08-31 | TD CowenTyler Van Buren |
Initiates coverage on | Buy | — |
| 2026-08-31 | Jefferies |
Initiates coverage on | Buy | $48 |
| 2026-08-31 | Cantor FitzgeraldOlivia Brayer Saunders |
Initiates coverage on | Overweight | $40 |
| 2026-08-31 | StifelJames Condulis |
Initiates coverage on | Buy | $45 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $25.02
- Market Cap
- $2.25 billion
- 52-Week Range
- $24.30 – $32.00
- Average Volume
- 455K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.